In situ hybridisation (fluorescent for FISH and chromogenic for CISH) uses probes to analyse genetic changes (amplifications, deletions, translocations) in tumours. These probes are used to classify tumours (particularly in the case of lymphomas and soft tissue tumours) and identify prognostic factors or therapeutic targets for certain tumours (in the case of breast cancers or lung adenocarcinomas).


Slides/blocks or cytological (including stained) preparations can be used.



The following probes are available in our range:


Breast and stomach

  • HER2/CEN 17 amplification 17q12



  • ALK translocation, probe: BA, 2p23
  • ROS1 translocation, probe: BA, 6q22
  • RET translocation, probe: BA, 10q11
  • MET/CEP7 amplification 7q31/7p11.1



  • MYC translocation, probe: BA, 8q24
  • BCL2 translocation, probe: BA, 18q21
  • BCL6 translocation, probe: BA, 3q27
  • CCND1 translocation, probe: BA, 11q13
  • MALT1 translocation, probe: BA, 18q21



  • MDM2/CEN 12 amplification 12q15



Your contact person

PD DrDavide Soldini, institute director

Head molecular pathology
Specialist in Pathology and Molecular Pathology FMH

044 269 99 28

DrSimone Brandt

Deputy Lead Molecular Pathology
Specialist in Pathology and Molecular Pathology FMH

044 269 99 76

Dr. med. vet. Ulrike Camenisch Gross

DrUlrike Camenisch Gross

Research assistant

044 269 99 49

Kati Seidl Spirig - medica

DrKati Seidl Spirig

Research assistant

044 269 99 49

Our Molecular Pathology is an SIWF certified continuing education center.

Diese Webseite verwendet Cookies, um bestimmte Funktionen zu ermöglichen und das Angebot zu verbessern. Indem Sie hier fortfahren, stimmen Sie der Nutzung von Cookies zu. Mehr Informationen